Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy

Aim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).

Material and methods. The study included 140 hypertensive patients who received atorvastatin (Liprimar) 20 mg/day in addition to antihypertensive therapy for a year, which was later replaced by rosuvastatin (Rosucard) in the following doses: 10 mg/day (n=96), 20 mg/day (n=24), 40 mg/day (n=26). Patients underwent standard clinical and paraclinical investigations. In the blood serum of patients, the levels of MMP-1, MMP-9 and TIMP-1, TIMP-4 were determined.

Results. Patients who used rosuvastatin at a dose of 40 mg/day had a more pronounced decrease in MMP-1 than those treated with rosuvastatin at a dose of 10 and 20 mg/day (p<0,05), while there were no differences in MMP-1 when using low and medium doses. Rosuvastatin had a less pronounced effect on MMP-9 than on MMP-1, while increasing the dose of rosuvastatin did not affect the intensity of MMP-9 reduction (p>0,05). The content of TIMP-1 and TIMP-4 increased when taking rosuvastatin, while a more pronounced dose-dependent increase in TIMP-1 was observed with rosuvastatin 20 mg/day and 40 mg/day. In addition, the largest increase in TIMP-4 was observed when using rosuvastatin at a dose of 40 mg/day. Atorvastatin had no significant effect on MMP-1 and MMP-9, as well as TIMP-1 and TIMP-4.

Conclusion. Long-term rosuvastatin therapy (10 mg/day, 20 mg/day, 40 mg/day) as part of the complex therapy of cardiovascular patients affects the metabolism of vascular wall elastin and collagen, reducing the level of MMP-1, MMP-9 and increasing the content of TIMP-1, TIMP-4 in the blood.

1. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.

2. Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) Кобалава Ж. Д., doi:10.15829/1560-4071-2020-3-3786.

3. Portnova EV. Analysis of target organ damage in patients with hypertension and supraventricular arrhythmias against the background of cognitive impairment. Fundamental Research. 2013;9(3):448-52. (In Russ.)

4. Osadchuk MA, Solodenkova KS. Mediators of inflammation: the role in development of vascular lesions and cardiovascular risk evaluation. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2016;9(4):63-72. (In Russ.) doi:10.17116/kardio20169463-72.

5. Ostroumova ОD, Kochetkov AI, Kopchenov II, et al. The hardness of the vessel wall in patients with arterial hypertension. Systemic Hypertension. 2015;12(2):43-8. (In Russ.) doi:10.26442/SG29073.

6. Fatenkov OV, Simerzin VV, Gagloeva IV, et al. Endothelial dysfunction as predictor of subclinical and manifest atherosclerosis. Science and Innovations in Medicine. 2018;3(3):39-46. (In Russ.) doi:10.35693/2500-1388-2018-0-3-39-46.

7. Kac YаA, Parhonyuk EV, Akimova NS. Stiffness of the vascular wall from the standpoint of connective tissue damage in cardiovascular diseases. Fundamental Research. 2013;5(3):189-95. (In Russ.)

8. Kolpakova AF. Disruptions of elastic arteries properties and endothelial function: modern methods for correction and prevention. Cardiovascular Therapy and Prevention. 2015;14(3):75-81. (In Russ.) doi:10.15829/1728-8800-2015-3-75-81.

9. Golikov AP, Boytsov SA, Mihin VP, et al. Free radical oxidation and cardiovascular disease: correction with antioxidants. Physician. 2003;4:1-5. (In Russ.)

10. Shevchenko OP, Shevchenko АО. Angiotensin II and myocardial infarction. Rational Pharmacotherapy in Cardiology. 2008;4(3):105-10. (In Russ.) doi:10.20996/1819-6446-2008-4-3-105-110.

11. Barsukov AV, Kornejchuk NN, Shustov SB. High-grade arterial hypertension: from symptom to diagnosis. Vestnik SeveroZapadnogo gosudarstvennogo medicinskogo universiteta imeni I. I. Mechnikova. 2017;9(2):7-18. (In Russ.) Барсуков А. В., doi:10.17816/mechnikov2017927-18.

12. Mikhin VP, Zhilyaeva YuA, Vorotyntseva VV, et al. Hypolipidemic and pleiotropic efficacy of rosuvastatin in arterial hypertension patients of high cardiovascular risk in long-term outpatient follow-up. Russian Journal of Cardiology. 2016;(12):90-6. (In Russ.) doi:10.15829/1560-4071-2016-12-90-96.

13. Mihin VP, Zhilyaeva YuA, Chernyatina MA, et al. Hypolipidemic and pleiotropic efficacy of generic statins in patients with high cardiovascular risk in outpatient practice. Russian Medical Journal. 2016; 19:1263-70. (In Russ.) doi:10.15829/1560-4071-2016-12-90-96.

14. Okunevich VI. Hypolipidemic therapy of dyslipoproteidemia with statins: their role in the complex treatment of atherosclerosis. Reviews on clinical pharmacology and drug therapy. 2004;3(4):2-14. (In Russ.) doi:10.17816/RCF193291-301.

15. Yakovenko EI, Mamedov MN. Effect of metabolic effects of statins on clinical manifestations of atherosclerosis. Russian Journal of Cardiology. 2012;(2):85-90. (In Russ.)

16. Drapkina OM, Palatkina LO, Zyatenkova EV. Pleiotropic effects of statins. action on vascular rigidity. Vrach (The Doctor). 2012;9:5-9. (In Russ.)

17. Semenova AE, Sergienko IV. The place of pitavastatin in the treatment and prevention of cardiovascular diseases. Atherosclerosis and dyslipidemia. 2017;3:33-45. (In Russ.)

18. Drapkina OM, Gegenava BB. Statins and carbohydrate metabolism. Effective pharmacotherapy. 2015;32:24-31. (In Russ.)

19. Bubnova MG. Undesirable effects of statin therapy: real evidence. Kardiosomatics. 2019;10(1):51-61. (In Russ.)

20. Ceron CS, Luizon MR. Plasma matrix metalloproteinases in coronary artery disease patients. Eur J Clinical Investigation. 2016;46(1):104-5. doi:10.1111/eci.12537.

21. Prudnikov AR, Schupakova AN. Matrix metalloproteinases: role in the development of myocardial postinfarction remodeling. Regional blood circulation and microcirculation. 2018;17(1):13-24. (In Russ.) doi:10.24884/1682-6655-2018-17-1-13-24.

22. Grigorkevich OS, Mokrov GV, Kosova LYu. Matrix metalloproteinases and their inhibitors. Pharmacokinetics and Pharmacodynamics. 2019;(2):3-16. (In Russ.) doi:10.24411/2587-7836-2019-10040.

23. Ezhov MV, Sergienko IV, Aronov DM, et al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Atherosclerosis and dyslipidemia. 2017;3(28):5-22. (In Russ.)

24. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113(17):2089-96. doi:10.1161/CIRCULATIONAHA.105.573865.

25. Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(2):372. doi:10.1161/01.ATV.0000151373.33830.41.

26. Castro MM, Rizzi E, Figueiredo-Lopes L, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis. 2008;198(2):320-31. doi:10.1016/j.atherosclerosis.2007.10.011.

27. Flamant M, Placier S, Dubroca C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension. 2007;50(1):212-8. doi:10.1161/HYPERTENSIONAHA.107.089631.

28. Sluijter JP, de Kleijn DP, Pasterkamp G. Vascular remodeling and protease inhibition — bench to bedside. Cardiovasc Res. 2006;69(3):595-603. doi:10.1016/j.cardiores.2005.11.026.

29. Basalyga DM, Simionescu DT, Xiong W, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation. 2004;110(22):3480-7. doi:10.1161/01.CIR.0000148367.08413.E9.

30. Valente FM, de Andrade DO, Cosenso-Martin LN, et al. Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis. BMC Cardiovasc Disord. 2020;20(1):132. doi:10.1186/s12872-020-01412-5.